Login to Your Account



Pancreas Data 'Overpower'? Celgene Phase III: More Later

By Randy Osborne
Staff Writer

Tuesday, November 13, 2012
Top-line data from a Phase III trial with Abraxane plus gemcitabine in pancreatic cancer by Celgene Corp.'s subsidiary Celgene International Sàrl suggested a benefit over the chemotherapy agent alone in overall survival (OS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription